Yesterday’s publication of PriceWaterhouseCooper’s evaluation of the biotechnology industry provides some sobering reading.  Amongst the doom and gloom there’s promise and some pointers for where this industry’s service providers should look for securing and growing Read more...

I was absent-mindedly driving my children to school yesterday with one ear on the radio when that otherwise irritating “Thought For The Day” came on.  Normally I’d switch off at this point as I hate pious witterings first thing in the morning (or anytime, come to think of it) Read more...

PharmaDiagnostics is an as-yet little known but ambitious company which has found out how to screen for molecule interactions and properties in high throughput formats, without using radioactive or fluorescent labeling or specialized equipment.  Their clever discovery has led to the development Read more...

It seems that most biotechs are seriously behind the curve when it comes to considering publicity as part of their aim to raise customer and investor awareness.   They often gauge their level of PR investment purely by the number of press releases they send out a month. Directors will ask for Read more...

There comes a point in a biotech’s lifetime when bringing in the business requires more than just the founder.   The person who the company has relied on to get onto the podium at conferences, be invited in to big pharma to trump the theories and applications of the technology and write Read more...

For young biotechnology companies, attracting seed and early stage funding has become increasingly difficult this year although anecdotal signs of recovery are beginning to emerge. The main reason: venture capital funds have been focusing on their existing portfolio companies who were holding off Read more...